Abstract
Two main causes of early mortality of acute promyelocytic leukemia (APL) are rewieved, unique type ofcoagulopathy typical for APL and differentiation syndrome sometimes complicating treatment of APL with all-trans retinoic acid (ATRA) or arsenic trioxide (ATO). The information covers analysis of the patophysiologies of both conditions and also recommendations considering treatments and preventive measures.
MeSH terms
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Agents / therapeutic use
-
Arsenic Trioxide
-
Arsenicals / adverse effects*
-
Arsenicals / therapeutic use
-
Disseminated Intravascular Coagulation / etiology*
-
Hemorrhage / etiology
-
Humans
-
Leukemia, Promyelocytic, Acute / complications
-
Leukemia, Promyelocytic, Acute / drug therapy*
-
Leukocytosis / chemically induced*
-
Oxides / adverse effects*
-
Oxides / therapeutic use
-
Respiratory Insufficiency / chemically induced*
-
Syndrome
-
Thrombocytopenia / etiology
-
Tretinoin / adverse effects*
-
Tretinoin / therapeutic use
Substances
-
Antineoplastic Agents
-
Arsenicals
-
Oxides
-
Tretinoin
-
Arsenic Trioxide